Pentewar Ganesh Satyadeo, Parab Sapna Ramkrishna
Department of Pharmacology, MIMER Medical College, Talegaon Dabhade, India.
Sushrut ENT Hospital and Dr. Khan's ENT Research Center, Talegaon Dabhade, India.
Indian J Otolaryngol Head Neck Surg. 2023 Apr;75(Suppl 1):928-933. doi: 10.1007/s12070-023-03488-9. Epub 2023 Jan 29.
Allergic rhinitis (AR) is a chronic inflammatory disease induced by IgE mediated reaction and identified clinically by presence of nasal discharge, sneezing, itching and nasal congestion. Aim of this study was to determine Serum IgE level which is an important indicator of AR. To analyse the diagnostic significance of serum IgE level and their pharmacoeconomic status in the management of AR with commonly used antihistaminic. Estimation of serum IgE can serve as a simple and reliable investigative tool in the diagnostic and management of AR. Fifty two adult patient with history of allergic rhinitis were randomly divided into four study groups and administered either Cetirizine, Levocetirizine, Loratidine or Fexofenadine respectively for one week. Blood samples were analysed to determine serum IgE level and the results were subjected to statistical analysis. The mean value and standard deviation were obtained and tabulated using paired t test. A total 52 patient were divided into four group, 13 in each group of age between 18 and 65 years (mean age 33.73 ± 10.23 years); 48.08% females and 51.92% male were randomized. Mean compliance with treatment was 100% for all study groups. The mean serum IgE level was significantly reduced in Levocetirizine as compared to Cetirizine, Loratidine and Fexofenadine groups. Levocetirizine controls the symptoms of AR better as compared to Cetirizine, Loratidine and Fexofenadine and is a better choice due to its cost effectiveness, tolerability and safety profile.
变应性鼻炎(AR)是一种由IgE介导的反应诱发的慢性炎症性疾病,临床上通过鼻分泌物、打喷嚏、瘙痒和鼻塞来诊断。本研究的目的是测定血清IgE水平,这是AR的一项重要指标。分析血清IgE水平在常用抗组胺药治疗AR中的诊断意义及其药物经济学状况。血清IgE的测定可作为AR诊断和治疗中一种简单可靠的检查工具。52例有变应性鼻炎病史的成年患者被随机分为四个研究组,分别给予西替利嗪、左西替利嗪、氯雷他定或非索非那定,为期一周。分析血样以测定血清IgE水平,并对结果进行统计分析。采用配对t检验获得平均值和标准差并制成表格。总共52例患者分为四组,每组13例,年龄在18至65岁之间(平均年龄33.73±10.23岁);随机分组中女性占48.08%,男性占51.92%。所有研究组的平均治疗依从性均为100%。与西替利嗪、氯雷他定和非索非那定组相比,左西替利嗪组的平均血清IgE水平显著降低。与西替利嗪、氯雷他定和非索非那定相比,左西替利嗪能更好地控制AR症状,且因其成本效益、耐受性和安全性,是更好的选择。